Strategies for and advances in the development of Staphylococcus aureus prophylactic vaccines.
about
Adult vaccinationA recombinant clumping factor A-containing vaccine induces functional antibodies to Staphylococcus aureus that are not observed after natural exposureThe potential use of toxin antibodies as a strategy for controlling acute Staphylococcus aureus infections.Opsonic and protective properties of antibodies raised to conjugate vaccines targeting six Staphylococcus aureus antigens.Regulation of Staphylococcus aureus MntC expression and its role in response to oxidative stressIdentification of the immunodominant regions of Staphylococcus aureus fibronectin-binding protein A.Colonization, pathogenicity, host susceptibility, and therapeutics for Staphylococcus aureus: what is the clinical relevance?A Multiple Antigenic Peptide Mimicking Peptidoglycan Induced T Cell Responses to Protect Mice from Systemic Infection with Staphylococcus aureus.Monoclonal Antibody Targeting Staphylococcus aureus Surface Protein A (SasA) Protect Against Staphylococcus aureus Sepsis and Peritonitis in Mice.Staphylococcus aureus manganese transport protein C is a highly conserved cell surface protein that elicits protective immunity against S. aureus and Staphylococcus epidermidis.Natural antibodies in normal human serum inhibit Staphylococcus aureus capsular polysaccharide vaccine efficacy.Prevention of Staphylococcus aureus infections by glycoprotein vaccines synthesized in Escherichia coli.Development of a multicomponent Staphylococcus aureus vaccine designed to counter multiple bacterial virulence factors.Vaccines in clinical trials: infectious disease.
P2860
Q26824961-8C7AF0EF-3592-4440-99E8-C5BDF3CB4B26Q28714292-6C6FFDCF-5957-46FF-8B10-3A0D66FE2D8DQ30415990-1F2BBC7E-9FC5-4906-BCB2-73E590095C09Q34450382-4B3FEA5E-9201-4FB5-A493-157243AD8AD5Q35035720-512A257D-86E6-41A1-ADB0-D0C68F9CF6D5Q35149380-BFD01EA7-0E33-425C-AD23-521E75A26F36Q35736907-ED0603D6-B0E7-44AD-8581-2EEB88142CC1Q35758457-869700D5-B84D-4F13-A5D3-BE5C6211525FQ35939497-758E7D8C-99B8-472D-A975-8D730675B322Q35948026-9EFDF2D5-6521-4EBE-8810-557E1E97FCD8Q36486860-F358BD02-F0C9-4B81-93A0-B60853456D01Q37719754-EBD7F216-DD27-4549-9BB2-16F1794655F3Q38038043-67982ADB-B50C-4333-97D0-6CFFFF9BB859Q47980661-18B053E1-7360-4A27-B8E8-C45236BCB1E6
P2860
Strategies for and advances in the development of Staphylococcus aureus prophylactic vaccines.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on May 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Strategies for and advances in ...... aureus prophylactic vaccines.
@en
Strategies for and advances in ...... aureus prophylactic vaccines.
@nl
type
label
Strategies for and advances in ...... aureus prophylactic vaccines.
@en
Strategies for and advances in ...... aureus prophylactic vaccines.
@nl
prefLabel
Strategies for and advances in ...... aureus prophylactic vaccines.
@en
Strategies for and advances in ...... aureus prophylactic vaccines.
@nl
P2093
P2860
P356
P1476
Strategies for and advances in ...... aureus prophylactic vaccines.
@en
P2093
Annaliesa S Anderson
Jane Broughan
Richard Anderson
P2860
P304
P356
10.1586/ERV.11.54
P577
2011-05-01T00:00:00Z